2024
Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidenceThe Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes.
Wang R, Serper M, Taddei T, Kaplan D, Mahmud N. The Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes. The American Journal Of Gastroenterology 2024 PMID: 39051649, DOI: 10.14309/ajg.0000000000002976.Peer-Reviewed Original ResearchAssociated with hepatic decompensationAngiotensin-converting enzyme inhibitorsAssociated with reduced mortalityAngiotensin receptor blockersACE-I/ARBConverting enzyme inhibitorsCV-related mortalityHepatocellular carcinomaHepatic decompensationCox regressionAngiotensin receptor blocker exposureEnzyme inhibitorsVeterans Health AdministrationCalcium channel blockersSubsets of patientsChronic liver diseaseCause-specific hazard modelInverse probability treatmentIdentified new initiatorsOutcome of mortalityNew initiativesCirrhosis decompensationCompensated cirrhosisDecompensated cirrhosisChannel blockersScreening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosisW31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis
Haque L, Fiellin D, Bryant K, Edelman E, Justice A, Lim J, Re V, Marshall B, Taddei T, Tate J, Tetrault J, Williams E, McGinnis K. W31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis. Drug And Alcohol Dependence 2024, 260: 110649. DOI: 10.1016/j.drugalcdep.2023.110649.Peer-Reviewed Original ResearchIdentification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reportsMo1525 HIGH PREVALENCE OF BARIATRIC SURGERY AMONG PATIENTS PRESENTING WITH ALCOHOL-ASSOCIATED HEPATITIS
Thompson R, Narayanan P, Mistry P, Taddei T, Rabiee A. Mo1525 HIGH PREVALENCE OF BARIATRIC SURGERY AMONG PATIENTS PRESENTING WITH ALCOHOL-ASSOCIATED HEPATITIS. Gastroenterology 2024, 166: s-1679. DOI: 10.1016/s0016-5085(24)04319-1.Peer-Reviewed Original ResearchMo1477 DEVELOPMENT AND VALIDATION OF CASE-FINDING ALGORITHMS TO IDENTIFY CHOLANGIOCARCINOMA AND ITS SUBTYPES IN VETERANS HEALTH ADMINISTRATION DATA
Ferrante N, Hubbard R, Weinfurtner K, Mezina A, Newcomb C, Furth E, Bhattacharya D, Njei B, Taddei T, Singal A, Hoteit M, Park L, Kaplan D, Re V. Mo1477 DEVELOPMENT AND VALIDATION OF CASE-FINDING ALGORITHMS TO IDENTIFY CHOLANGIOCARCINOMA AND ITS SUBTYPES IN VETERANS HEALTH ADMINISTRATION DATA. Gastroenterology 2024, 166: s-1056. DOI: 10.1016/s0016-5085(24)02898-1.Peer-Reviewed Original ResearchSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights.
Rose M, Kennedy E, Abou-Alfa G, Finn R, Gade T, Kelley R, Taddei T, Gordan J. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights. JCO Oncology Practice 2024, 20: 1035-1039. PMID: 38662970, DOI: 10.1200/op.24.00189.Peer-Reviewed Original ResearchOrganizational and Implementation Factors Associated with Cirrhosis Care in the Veterans Health Administration
McCurdy H, Nobbe A, Scott D, Patton H, Morgan T, Bajaj J, Yakovchenko V, Merante M, Gibson S, Lamorte C, Baffy G, Ioannou G, Taddei T, Rozenberg-Ben-Dror K, Anwar J, Dominitz J, Rogal S. Organizational and Implementation Factors Associated with Cirrhosis Care in the Veterans Health Administration. Digestive Diseases And Sciences 2024, 69: 2008-2017. PMID: 38616215, DOI: 10.1007/s10620-024-08409-6.Peer-Reviewed Original ResearchVeterans Affairs (VA) medical centersCirrhosis careDashboard usePopulation management toolCare processesSurveillance ratesDepartment of Veterans Affairs (VA) medical centersFactors associated with high performanceVeterans Health AdministrationHCC surveillanceSpecialty carePerceived barriersData Warehouse dataHealth AdministrationImplementation evaluationLinear regression modelsCareGastroenterology serviceMedical CenterMultivariate modelRegression modelsQuality measuresVeteransRate differencesWarehouse dataSafety of naltrexone in patients with cirrhosis
Thompson R, Taddei T, Kaplan D, Rabiee A. Safety of naltrexone in patients with cirrhosis. JHEP Reports 2024, 6: 101095. PMID: 38961852, PMCID: PMC11220533, DOI: 10.1016/j.jhepr.2024.101095.Peer-Reviewed Original ResearchDrug-induced liver injuryRoussel Uclaf Causality Assessment MethodAlcohol use disorderInitiation of naltrexoneSafety of naltrexoneUse disorderRetrospective studyDevelopment of drug-induced liver injuryRoussel Uclaf Causality Assessment Method scoreLiver injuryLiver diseaseRetrospective study of patientsTreatment of alcohol use disordersTreat alcohol use disorderLiver enzyme elevationAlcohol-related cirrhosisCohort of patientsAlkaline phosphatase elevationDiagnosis of cirrhosisStudy of patientsAssociated with developmentCausality Assessment MethodPrescribed naltrexoneDecompensated cirrhosisEnzyme elevationTransjugular Intrahepatic Portosystemic Shunt Linked to Increased Risk of Hepatocellular Carcinoma: A VA Matched Cohort Study
Bansal S, Taddei T, Wells R, Serper M, Bittermann T, Mahmud N, Kaplan D. Transjugular Intrahepatic Portosystemic Shunt Linked to Increased Risk of Hepatocellular Carcinoma: A VA Matched Cohort Study. Journal Of Clinical And Translational Hepatology 2024, 12: 534-538. PMID: 38779520, PMCID: PMC11106346, DOI: 10.14218/jcth.2023.00554.Peer-Reviewed Original ResearchDetection of hepatocellular carcinoma methylation markers in salivary DNA
Mezzacappa C, Wang Z, Lu L, Risch H, Taddei T, Yu H. Detection of hepatocellular carcinoma methylation markers in salivary DNA. Bioscience Reports 2024, 44: bsr20232063. PMID: 38457142, PMCID: PMC10958141, DOI: 10.1042/bsr20232063.Peer-Reviewed Original ResearchHepatocellular carcinoma screeningCase patientsHepatocellular carcinomaControl subjectsDiagnosis of hepatocellular carcinomaAssociated with hepatocellular carcinomaScreening testSalivary DNASaliva-based testCpG sitesStudy of risk factorsSalivary DNA methylationDNA methylationViral hepatitisCirculating DNAAlterations to DNA methylationRisk factorsMethylation markersPatientsRegulation of cell cycle progressionBlood samplesCell cycle progressionAffected individualsAlternative to blood samplingMultiple comparisonsSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan J, Kennedy E, Abou-Alfa G, Beal E, Finn R, Gade T, Goff L, Gupta S, Guy J, Hoang H, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb A, Kelley R, Kortmansky J, Leaf A, Remak W, Sohal D, Taddei T, Wilson Woods A, Yarchoan M, Rose M. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal Of Clinical Oncology 2024, 42: 1830-1850. PMID: 38502889, DOI: 10.1200/jco.23.02745.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsAdvanced hepatocellular carcinomaSecond-line therapyFirst-line treatmentRandomized controlled trialsHepatocellular carcinomaSystemic therapyFirst-lineChild-Pugh class A liver diseaseEastern Cooperative Oncology Group performance status 0Child-Pugh class A patientsSecond-line therapy optionsFirst-line settingPerformance status 0Third-line therapyFirst-line therapyClass A patientsEvidence-based guidelinesTolerated sorafenibStatus 0A patientsMechanism of actionTherapy optionsClinical decision-makingGuideline updateAASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Sterling R, Patel K, Duarte-Rojo A, Asrani S, Alsawas M, Dranoff J, Fiel M, Murad M, Leung D, Levine D, Taddei T, Taouli B, Rockey D. AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology 2024 PMID: 38489523, DOI: 10.1097/hep.0000000000000845.Peer-Reviewed Original ResearchAASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
Sterling R, Asrani S, Levine D, Duarte-Rojo A, Patel K, Fiel M, Leung D, Taouli B, Alsawas M, Murad M, Dranoff J, Taddei T, Rockey D. AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension. Hepatology 2024 PMID: 38489663, DOI: 10.1097/hep.0000000000000844.Peer-Reviewed Original ResearchAccuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
Patel K, Asrani S, Fiel M, Levine D, Leung D, Duarte-Rojo A, Dranoff J, Nayfeh T, Hasan B, Taddei T, Alsawaf Y, Saadi S, Majzoub A, Manolopoulos A, Alzuabi M, Ding J, Sofiyeva N, Murad M, Alsawas M, Rockey D, Sterling R. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology 2024 PMID: 38489517, DOI: 10.1097/hep.0000000000000842.Peer-Reviewed Original ResearchAminotransferase-to-platelet ratio indexChronic liver diseaseNonalcoholic fatty liver diseaseHepatitis B virusBlood-based biomarkersLiver diseaseFIB-4HIV-HCV co-infectionCo-infectionFIB-4 <Alternative to liver biopsyFIB-4 >Pre-test probabilityBlood-based testLiver disease assessmentSystematic reviewStaging liver fibrosisComprehensive search of databasesHIV-HCVFatty liver diseaseProportional odds ratiosAdvanced fibrosisLiver biopsyViral hepatitisB virusAASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Sterling R, Duarte-Rojo A, Patel K, Asrani S, Alsawas M, Dranoff J, Fiel M, Murad M, Leung D, Levine D, Taddei T, Taouli B, Rockey D. AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology 2024 PMID: 38489518, DOI: 10.1097/hep.0000000000000843.Peer-Reviewed Original Research
2023
Deploying a national clinical text processing infrastructure
McManus K, Stringer J, Corson N, Fodeh S, Steinhardt S, Levin F, Shotqara A, D’Auria J, Fielstein E, Gobbel G, Scott J, Trafton J, Taddei T, Erdos J, Tamang S. Deploying a national clinical text processing infrastructure. Journal Of The American Medical Informatics Association 2023, 31: 727-731. PMID: 38146986, PMCID: PMC10873837, DOI: 10.1093/jamia/ocad249.Peer-Reviewed Original ResearchCommunity-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study.
Mezzacappa C, Rossi R, Jaffe A, Taddei T, Strazzabosco M. Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study. Cancer Epidemiology Biomarkers & Prevention 2023, 33: 270-278. PMID: 38059831, PMCID: PMC10872555, DOI: 10.1158/1055-9965.epi-23-0902.Peer-Reviewed Original ResearchHCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis
Mezzacappa C, Mahmud N, Serper M, John B, Taddei T, Kaplan D. HCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis. Hepatology Communications 2023, 7: e0344. PMID: 38055642, PMCID: PMC10984661, DOI: 10.1097/hc9.0000000000000344.Peer-Reviewed Original ResearchRate of HCCBlood glucose controlBG controlIncident HCCGlucose controlCox proportional hazards regressionEtiology of cirrhosisProportional hazards regressionUnited States veteransHemoglobin A1c measurementsCirrhosis careHgb A1cHCC ratesHazards regressionNational cohortHCC riskA1c measurementStates veteransCirrhosisHigh riskDiabetesSustained controlHCCControl stateCohort